Extracellular vesicles: Targeting the heart
- PMID: 36704471
- PMCID: PMC9871562
- DOI: 10.3389/fcvm.2022.1041481
Extracellular vesicles: Targeting the heart
Abstract
Cardiovascular diseases rank the highest incidence and mortality worldwide. As the most common type of cardiovascular disease, myocardial infarction causes high morbidity and mortality. Recent studies have revealed that extracellular vesicles, including exosomes, show great potential as a promising cell-free therapy for the treatment of myocardial infarction. However, low heart-targeting efficiency and short plasma half-life have hampered the clinical translation of extracellular vesicle therapy. Currently, four major types of strategies aiming at enhancing target efficiency have been developed, including modifying EV surface, suppressing non-target absorption, increasing the uptake efficiency of target cells, and utilizing a hydrogel patch. This presented review summarizes the current research aimed at EV heart targeting and discusses the challenges and opportunities in EV therapy, which will be beneficial for the development of effective heart-targeting strategies.
Keywords: cardiovascular diseases; exosome (vesicle); extracellular vesicles; myocardial infarction; target delivery.
Copyright © 2023 Yin and Jiang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Extracellular vesicles in cardiovascular disease.Adv Clin Chem. 2021;103:47-95. doi: 10.1016/bs.acc.2020.08.006. Epub 2020 Oct 1. Adv Clin Chem. 2021. PMID: 34229852 Review.
-
Boosting extracellular vesicle secretion.Biotechnol Adv. 2022 Oct;59:107983. doi: 10.1016/j.biotechadv.2022.107983. Epub 2022 May 16. Biotechnol Adv. 2022. PMID: 35588952 Free PMC article. Review.
-
Extracellular vesicles in atherothrombosis and cardiovascular disease: Friends and foes.Atherosclerosis. 2021 Aug;330:61-75. doi: 10.1016/j.atherosclerosis.2021.07.002. Epub 2021 Jul 6. Atherosclerosis. 2021. PMID: 34256307 Review.
-
Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure.J Heart Lung Transplant. 2016 Jun;35(6):795-807. doi: 10.1016/j.healun.2016.01.013. Epub 2016 Jan 19. J Heart Lung Transplant. 2016. PMID: 27041495
-
Engineering strategies for customizing extracellular vesicle uptake in a therapeutic context.Stem Cell Res Ther. 2022 Mar 28;13(1):129. doi: 10.1186/s13287-022-02806-2. Stem Cell Res Ther. 2022. PMID: 35346367 Free PMC article. Review.
Cited by
-
Advances in the design, generation, and application of tissue-engineered myocardial equivalents.Front Bioeng Biotechnol. 2023 Sep 22;11:1247572. doi: 10.3389/fbioe.2023.1247572. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37811368 Free PMC article. Review.
-
Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction.Molecules. 2024 May 21;29(11):2415. doi: 10.3390/molecules29112415. Molecules. 2024. PMID: 38893291 Free PMC article. Review.
-
Engineering extracellular vesicles for targeted therapeutics in cardiovascular disease.Front Cardiovasc Med. 2024 Dec 19;11:1503830. doi: 10.3389/fcvm.2024.1503830. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39749310 Free PMC article. Review.
-
Charting the Path: Navigating Embryonic Development to Potentially Safeguard against Congenital Heart Defects.J Pers Med. 2023 Aug 15;13(8):1263. doi: 10.3390/jpm13081263. J Pers Med. 2023. PMID: 37623513 Free PMC article. Review.
-
Exosomes and their derivatives as biomarkers and therapeutic delivery agents for cardiovascular diseases: Situations and challenges.J Transl Int Med. 2023 Dec 20;11(4):341-354. doi: 10.2478/jtim-2023-0124. eCollection 2023 Dec. J Transl Int Med. 2023. PMID: 38130647 Free PMC article.
References
-
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). (2018) 392:1789–858. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials